Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of “Moderate Buy” by Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been assigned a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $41.44.

Several analysts recently commented on the stock. Royal Bank of Canada restated an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. B. Riley reaffirmed a “buy” rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th.

Arrowhead Pharmaceuticals Stock Up 4.0 %

Shares of ARWR opened at $12.69 on Thursday. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -2.45 and a beta of 0.92. Arrowhead Pharmaceuticals has a 52 week low of $11.89 and a 52 week high of $30.41. The stock’s 50-day moving average price is $17.70 and its 200-day moving average price is $19.43. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). On average, sell-side analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current year.

Insider Activity at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 51,425 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the sale, the chief executive officer now directly owns 4,062,377 shares in the company, valued at $61,220,021.39. This represents a 1.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider James C. Hamilton sold 32,729 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $19.82, for a total value of $648,688.78. Following the completion of the sale, the insider now directly owns 272,122 shares of the company’s stock, valued at approximately $5,393,458.04. This represents a 10.74 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 274,797 shares of company stock valued at $4,830,279. 4.30% of the stock is owned by insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ARWR. Intech Investment Management LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $659,000. Charles Schwab Investment Management Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 1.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,006,935 shares of the biotechnology company’s stock valued at $19,504,000 after buying an additional 12,574 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 941.0% during the 3rd quarter. Fisher Asset Management LLC now owns 122,260 shares of the biotechnology company’s stock worth $2,368,000 after buying an additional 110,516 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $149,000. Finally, BNP Paribas Financial Markets lifted its holdings in Arrowhead Pharmaceuticals by 40.1% in the third quarter. BNP Paribas Financial Markets now owns 55,188 shares of the biotechnology company’s stock valued at $1,069,000 after acquiring an additional 15,784 shares during the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.